AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34474301
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of natalizumab (4-week intervals)
Trial: 33077341
Drug: Peg–IFN–α2a 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg–IFN–α2a 180 μg
Trial: 33077341
Drug: Ropeginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropeginterferon alfa‐2b 270 μg
Trial: 33077341
Drug: Ropeginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropeginterferon alfa‐2b 360 μg
Trial: 33077341
Drug: Ropeginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropeginterferon alfa‐2b 450 μg
Trial: 35673948
Drug: Phenobarbitone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone (20 mg/kg) followed by Levetiracetam
Trial: 36482794
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low nicotine content (VLNC; 0.4 mg/g; n = 29)
Trial: 36482794
Drug: Normal nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal nicotine content (NNC; 15.8 mg/g; n = 31)
Trial: 33594488
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Insulin
Trial: 33594488
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Insulin
Trial: 36006603
Drug: Wearable fitness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable fitness trackers used for 12 weeks during CBT treatment
Trial: 34621497
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing Therapy (EMDR)
Trial: 34621497
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Writing Therapy (CBWT)
Trial: 33423318
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (budesonide 400 μg/day)
Trial: 33423318
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of budesonide with oral statin (simvastatin 10 mg/day)
Trial: 33423318
Drug: Neutralisation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralisation of IL-10 with recombinant specific blocking antibody
Trial: 33141609
Drug: Empagliflozin (SGLT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (SGLT2 inhibitor)
Trial: 34563804
Drug: Binaural Sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binaural Sound Therapy (BST)
Trial: 34715032
Drug: M5717 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M5717 (400 mg)
Trial: 34715032
Drug: M5717 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M5717 (800 mg)
Trial: 34715032
Drug: M5717 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M5717 (600 mg)
Trial: 34715032
Drug: M5717 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M5717 (1000 mg)
Trial: 37228028
Drug: Subcutaneous belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous belimumab 200 mg
Trial: 39496199
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges
Trial: 32840419
Drug: Accelerated Partial-Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Partial-Breast Irradiation (APBI) - 30 Gy in 5 once-daily fractions
Trial: 34547340
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus Saline Solution (LS)
Trial: 32891234
Drug: Smaller financial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smaller financial incentive (10,000 TZS; about US$4.50) for monthly clinic attendance
Trial: 32891234
Drug: Larger financial
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger financial incentive (22,500 TZS; about US$10.00) for monthly clinic attendance
Trial: 36273186
Drug: Intensity-modulated proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated proton therapy (IMPT)
Trial: 35818418
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng (KRG) capsule
Trial: 32726041
Drug: Amoxicillin Capsules
RxNorm normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin Capsules (Amoxil)
Trial: 34981352
Drug: External facilitation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External facilitation intervention including assessment of local barriers/facilitators, formation of a local implementation team, site visit for action planning and training/education, cross-facility quarterly calls, monthly coaching calls, and consultation.
Trial: 33347565
Drug: TU2670 (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU2670 (GnRH antagonist) 20 mg
Trial: 33347565
Drug: TU2670 (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU2670 (GnRH antagonist) 40 mg
Trial: 33347565
Drug: TU2670 (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU2670 (GnRH antagonist) 80 mg
Trial: 33347565
Drug: TU2670 (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU2670 (GnRH antagonist) 160 mg
Trial: 36241968
Drug: Penehyclidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penehyclidine (0.5 mg)
Trial: 36241968
Drug: TIVA alone
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA alone (normal saline 5 ml)
Trial: 34199001
Drug: Dexmedetomidine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2.5 mcg/kg (D)
Trial: 34199001
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 mcg/kg and ketamine 1 mg/kg (DK)
Trial: 32870726
Drug: EMS diagnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMS diagnosis of 'seizure-active' with benzodiazepine treatment
Trial: 32740328
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure at the Baihui (GV20), Fengchi (GB20), Neiguan (PC6), and Shenmen (HT7) points over a 12-week period
Trial: 36367709
Drug: Ticagrelor (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (60 mg)
Trial: 33945964
Drug: Ankle-related physical
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankle-related physical therapy (control group)
Trial: 33880959
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dexamethasone added to 30 mL of 0.5% ropivacaine
Trial: 33880959
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone added to 30 mL of 0.5% ropivacaine
Trial: 33880959
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg dexamethasone (control group)
Trial: 35612971
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of Physician's Choice (TPC) - intravenous doxorubicin 60 mg/m2 every 3 weeks or paclitaxel 80 mg/m2 weekly (3 weeks on/1 week off)
Trial: 33884702
Drug: Carbetocin 100
RxNorm normalized name: Carbetocin 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 mcg
Trial: 34603045
Drug: TRC150094 150
RxNorm normalized name: TRC150094
DrugBank: TRC150094 (DB16046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC150094 150 mg
Trial: 33534419
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) guided treatment
Trial: 38765567
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg once daily
Trial: 33250338
Drug: Placebo-controlled (Hidden)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-controlled (Hidden) administration of antidepressant medication for 8 weeks
Trial: 35689239
Drug: HLX01 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX01 (1000 mg intravenously on days 1 and 15, followed by 1000 mg on weeks 24 and 26)
Trial: 34933984
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention (monthly review of medications, patient education, medication adjustment advice)
Trial: 36203568
Drug: 1790GAHB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1790GAHB vaccine (1.5/25 µg)
Trial: 36203568
Drug: 1790GAHB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1790GAHB vaccine (6/100 µg)
Trial: 36203568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (active comparator vaccines)
Trial: 39531231
Drug: Present-Centered Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-Centered Therapy (PCT)
Trial: 32969946
Drug: Senna (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna (1.0 g)
Trial: 32969946
Drug: Magnesium Oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium Oxide (1.5 g)
Trial: 37976067
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/d)
Trial: 34103405
Drug: Tofacitinib modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib modified-release 11 mg once daily plus methotrexate
Trial: 36067506
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement containing Cannabis sativa oil, Boswellia serrata Roxb. Phytosome®, and Zingiber officinale extract
Trial: 35943968
Drug: Cognitive Refocusing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Refocusing Treatment for Insomnia (CRT‐I)
Trial: 35943968
Drug: Stimulus Control
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulus Control Treatment (SCT)
Trial: 32917925
Drug: Iron replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron replacement therapy (oral or intravenous)
Trial: 32917925
Drug: Biological assessments
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological assessments of iron status
Trial: 32669223
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs
Trial: 35099988
Drug: Faster intravenous
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster intravenous fluid bolus rates
Trial: 33546038
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg/6 h for 2 days, 4 mg/8 h for 2 days, 2 mg/6 h for 2 days, 2 mg/8 h for 2 days, 1 mg/8 h for 2 days, 1 mg/12 h for 2 days)
Trial: 35348642
Drug: Adjunct AF
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct AF surgery
Trial: 33383112
Drug: Aloe Vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe Vera vaginal cream
Trial: 36809193
Drug: E4 15
RxNorm normalized name: Ethinylestradiol 15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E4 15 mg
Trial: 36399023
Drug: E4 5
RxNorm normalized name: Ethinylestradiol 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E4 5 mg
Trial: 36399023
Drug: E4 10
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: E4 10 mg
Trial: 35219377
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg garadacimab
Trial: 35219377
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg garadacimab
Trial: 33875266
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine (50 EU)
Trial: 33875266
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine (100 EU)
Trial: 33875266
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine (150 EU)
Trial: 616493118
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (Cr) supplementation (0.3 g.kg‐1.d‐1 for 5 days followed by 0.1 g.kg‐1.d‐1 for 23 days)
Trial: 35467612
Drug: Positive rumination-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive rumination-based sports prescription (Experimental group)
Trial: 33245002
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone and metronidazole
Trial: 35509491
Drug: IV midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV midazolam and syrup (Group S)
Trial: 34531205
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (2 ?g/kg bolus, 1 ?g/kg/hour infusion up to 3 ?g/kg/hour)
Trial: 34531205
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg/kg bolus, intermittent bolus doses up to 2 mg/kg)
Trial: 34531205
Drug: Revised regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revised regimen of intravenous fentanyl (2 ?g/kg bolus, 2 ?g/kg/hour infusion up to 5 ?g/kg/hour)
Trial: 34531205
Drug: Revised regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revised regimen of intravenous ketamine (1 mg/kg bolus, intermittent bolus doses up to 4 mg/kg)
Trial: 34531205
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (revised regimen)
Trial: 34531205
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (revised regimen)
Trial: 33905680
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of antibiotics in a prehospital setting
Trial: 33905680
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of antibiotics
Trial: 32955967
Drug: Reproxalap 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks)
Trial: 32955967
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks) and prednisolone 1% ophthalmic solution (twice daily taper for 6 weeks)
Trial: 34703529
Drug: Haloperidol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2.5 mg/day with methadone (LD group)
Trial: 38171633
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) alone
Trial: 33788481
Drug: Magnetic beads
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic beads auricular point sticking therapy
Trial: 36083488
Drug: Wenshen Jianpi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wenshen Jianpi recipe (WJR) combined with antiretroviral therapy (ART)
Trial: 33126310
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with pantoprazole 40 mg once daily
Trial: 35917650
Drug: Palmitoylethanolamide (PEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoylethanolamide (PEA) 600 mg twice a day
Trial: 33518298
Drug: Xylanase supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylanase supplementation (100 mg per kg)
Trial: 32979855
Drug: Glucose-with-insulin (GwI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-with-insulin (GwI) infusions
Trial: 32979855
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for hyperkalaemia within the previous 24 hours
Trial: 34403424
Drug: Community-based mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based mass drug administration (MDA) with albendazole
Trial: 36094652
Drug: Closed-loop deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop deep brain stimulation (DBS) therapy
Trial: 32534645
Drug: Antibiotic shunt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic shunt
Trial: 36736921
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation therapy
Trial: 32615623
Drug: Telemedical services
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedical services for exclusive remote treatment
Trial: 36079092
Drug: Gait Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gait Group (GG) - robotic treatment for gait rehabilitation through an end-effector system
Trial: 34792482
Drug: Drug-Eluting Stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stent (DES)
Trial: 36072908
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg orally
Trial: 32245308
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin per day for 24 weeks
Trial: 36094772
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus intravenous methylprednisolone (IVMP) for 7 days
Trial: 34047303
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg b.i.d.
Trial: 35263518
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (1.1 GBq) after injections of recombinant human thyrotropin
Trial: 33095458
Drug: Laparoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic treatment
Trial: 32243402
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicine treatment
Trial: 33260063
Drug: Genotropin™ (originator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin™ (originator recombinant growth hormone)
Trial: 33260063
Drug: Criscy™ (biosimilar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Criscy™ (biosimilar recombinant growth hormone)
Trial: 32576258
Drug: Extended 6-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended 6-day treatment with artemether-lumefantrine and a single low-dose primaquine
Trial: 32576258
Drug: Standard 3-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 3-day treatment with artemether-lumefantrine (control)
Trial: 39441580
Drug: Upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 15 mg
Trial: 39441580
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg
Trial: 39331638
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg
Trial: 33734057
Drug: RPH-104 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RPH-104 treatment
Trial: 35247512
Drug: Leukocyte-poor platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte-poor platelet-rich plasma (Lp-PRP) injections (3 injections at the tendon repair site during surgery, at days 7 and 14 after surgery)
Trial: 35247512
Drug: Leukocyte-poor platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte-poor platelet-rich plasma (Lp-PRP) injections
Trial: 33705623
Drug: FAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC plus Simvastatin (40 mg/d orally)
Trial: 33705623
Drug: FAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC plus placebo (40 mg/d)